CD39 Expression Identifies Terminally Exhausted CD8+ T CellsPrakash Gupta, W. Nicholas Haining, Jernej Godec et al.|PLoS Pathogens|2015Cited by 390
Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunityMeng‐Ju Wu, Nabeel Bardeesy, Jonathan Sussman et al.|Science|2024Cited by 87
Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor modelJ. Bryan Iorgulescu, David A. Reardon, Neil Ruthen et al.|Frontiers in Immunology|2023Cited by 23
Abstract 606: Targeting the immune checkpoint PTPN2 with ABBV-CLS-484 inflames the tumor microenvironment and unleashes potent CD8+ T cell immunityArvin Iracheta‐Vellve, Robert T. Manguso, Hakimeh Ebrahimi-Nik et al.|Cancer Research|2022Cited by 8
Abstract ND06: ABBV-CLS-484: An active site PTPN2/N1 inhibitor that augments the immune response and sensitizes tumors to immune-mediated killingChristina K. Baumgartner, Philip R. Kym, Marcia N. Paddock et al.|Cancer Research|2022Cited by 7